ADHD White Paper Summary

BiogeniQ, ADHD, Pharmacogenetics

19 November 2018

At the forefront of innovations in health care is personalized medicine. Contrary to the current method of treating each patient in the manner that works best on average, personalized medicine aims to individualize treatments and prevention strategies based on unique molecular characteristics, such as a person’s DNA.


Personalized medicine has particularly made strides in pharmacogenetics, where DNA testing is used to make more informed decisions regarding treatments, thereby limiting trial and error and side effects.


Launched in 2016 by BiogeniQ, the ADHD Pharma profile is a pharmacogenetic test designed to guide treatment choices for attention deficit disorder with or without hyperactivity (ADHD). The test report is a tool that the attending physician uses to identify treatments that are potentially incompatible or for which dose adjustments would need to be considered.


BiogeniQ conducted a retrospective study of 52 clients in which participants were asked about their prescription history. Each participant noted which treatments had been prescribed and whether they were discontinued. Patients whose reports indicated a risk of incompatibility with a treatment prescribed to them prior to testing all reported a discontinuation of that treatment. This correlation demonstrates that the test can identify treatments that should be reconsidered or at least used with caution. In addition, the ADHD Pharma profile can help the doctor and patient understand why a treatment failed.


Often, when a treatment for ADHD does not work, there are few if any tools to help the clinician understand the reason for the failure and determine the next treatment plan. For some patients, this becomes an endless and discouraging process of trial and error. This new retrospective study demonstrates that the ADHD Pharma profile can indeed identify potentially incompatible treatments. Contrary to the usual process, the information provided by this test can allow the attending physician to make a more informed decision on the choice of treatment and limit the period of trial and error.


Learn more